# **Data supplement**


## Appendix S1

This appendix describes in detail the features, estimation, and performance assessment of the predictive models reported in the paper.

## **Features of the predictive models**

We developed predictive models for the probability of diagnosis of preeclampsia overall, preeclampsia with delivery before 37 weeks' gestation and preeclampsia with delivery from 37 weeks' gestation. Additional predictive models for the probability of preeclampsia before and from 37 weeks' gestation (irrespective of gestational length at delivery) were created. Each model included 20 baseline predictors (e.g. maternal characteristics and medical history) and two time-varying predictors that were not treated as continuous (plasma glucose: binary, if > 9 mmol/L, then positive from that date and onwards, and proteinuria that was categorical, if 1+ or >=2+, then treated as that from that date and onwards). The five continuous time-varying predictors (systolic blood pressure, diastolic blood pressure, hemoglobin, maternal weight and symphysis-fundal height) were included in the models by means of u-scores. For each time-varying predictor, a set of three u-scores captured the departure of each woman's trajectory from the non-preeclamptic population average trajectory with respect to three features: level, trend, and curvature.

Figure S1 illustrates these features with an example for systolic blood pressure, one of the time-varying predictors. The average trajectory of systolic blood pressure in the non-preeclamptic population is indicted by the solid curve, and that of a fictitious woman by a dashed curve. The observed measures of her systolic blood pressures are displayed as dots. The woman's trajectory has higher level, steeper trend, and more pronounced curvature, than the population average.



**Figure S1**. The non-preeclamptic population average trajectory of systolic blood pressure (solid curve), and the predicted trajectory (dashed curve) and the observed measures (dots) of a fictitious woman.

#### **Estimation of the predictive models**

We estimated the predictive models in three steps: first, we defined and estimated a mixed-effects model with data from the population of women without pre-eclampsia; second, we used the empirical best linear unbiased predictor to obtain the u-scores for level, trend, and curvature, for all women; third, we included the u-scores along with the other baseline predictors in logistic regression models. The following three subsections describe the three steps in detail.

## First step: define and estimate the trajectory of time-varying predictors


After excluding all the women with pre-eclampsia, we estimated the following mixed-effect model,

$$W_{i,j} = (\alpha_0 + u_{i,0}) + (\alpha_1 + u_{i,1}) \text{week}_{i,j} + (\alpha_2 + u_{i,2}) \text{week}_{i,j}^2 + e_{i,j}$$

where the subscript i indicated the woman, the subscript j the visit,  $W_{i,j}$  is the observed predictor  $W_{i,j}$ , week<sub>i,j</sub> the gestational week,  $u_{i,0}$ ,  $u_{i,1}$ ,  $u_{i,2}$  the random effects,  $e_{i,j}$  the residual term, and  $\alpha_0$ ,  $\alpha_1$ , and  $\alpha_2$  the regression coefficients.

Although the above second-order polynomial model was an approximation to the actual trajectories of the different time-varying predictors, we deemed it adequate to capture their main features, namely level, trend, and curvature. The level represented the average of the predictor if this was constant over time. The level was  $\alpha_0$  for the population and  $(\alpha_0 + u_{i,0})$  for the *i*-th woman. The trend represented the slope of the trajectory if this was linear. The trend was  $\alpha_1$  for the population and  $(\alpha_1 + u_{i,1})$  for the *i*-th woman. Finally, the curvature represented the convexity of the trajectory as measured by its second derivative. The curvature was  $\alpha_2$  for the population and  $(\alpha_2 + u_{i,2})$  for the *i*-th woman.

The random effects  $u_{i,0}$ ,  $u_{i,1}$ ,  $u_{i,2}$  represented the departure of the *i*-th woman's trajectory from the non-preclamptic population-average trajectory of the level, trend, and curvature, respectively. Figure S2 helps visualize their interpretation.



**Figure S2.** The distribution of the u-score in the non-preeclamptic population for any given feature (level, trend, and curvature) of a woman's trajectory. The x-axis indicates the standard deviations from the population average. When the u-score of a given feature and woman is equal to zero, that feature of that woman' trajectory is equal to population average. A positive (negative) u-score indicates that the feature is larger (smaller) than that of population.

The random vector  $u_i = (u_{i,0}, u_{i,1}, u_{i,2})'$  was assumed to follow a multivariate normal distribution with mean equal to the three-dimensional vector of zeros and covariance matrix equal to

$$G = \begin{bmatrix} \gamma_{0,0} & \gamma_{0,1} & \gamma_{0,2} \\ \gamma_{0,1} & \gamma_{1,1} & \gamma_{1,2} \\ \gamma_{0,2} & \gamma_{1,2} & \gamma_{2,2} \end{bmatrix}$$

The variance parameters  $\gamma_{0,0}$ ,  $\gamma_{1,1}$ , and  $\gamma_{2,2}$  were constrained to be positive. The remaining covariance parameters  $\gamma_{0,1}$ ,  $\gamma_{0,2}$ , and  $\gamma_{1,2}$  were left unconstrained. The residual term  $e_{i,j}$  in the mixed model was assumed to follow a zero-mean normal distribution with variance  $\sigma_e^2$ . The vector  $u_i$  and the residual  $e_{i,j}$  were assumed independent of each other and of the gestational week. The parameters  $\alpha$  and  $\gamma$  were estimated by maximizing the corresponding likelihood function (McCulloch et al 2008).

#### Second step: obtain the u-scores

For all the women in the sample, we obtained the u-scores with the empirical best linear unbiased predictor (EBLUP),

$$u_i = GZ_i'(Z_iGZ_i' + \sigma_e^2I_i)^{-1}(w_i - Z_i\alpha)$$

where the vector  $w_i$  contained the measures of the time-varying predictor at each visit,  $Z_i$  indicated the matrix with the j-th row equal to  $(1, \operatorname{week}_{i,j}, \operatorname{week}_{i,j}^2)$  for the j-th visit for the i-th woman, and  $I_i$  indicated the identity matrix. The number of rows of the matrices  $Z_i$  and  $I_i$  was equal to the number of visits for the i-th woman, which varied across women. The parameters  $\alpha$  and  $\gamma$  contained in the above expression were replaced with the estimates obtained in the first step, as described in the previous section.

The EBLUP has desirable properties and an interesting interpretation (McCulloch et al 2008). To predict a given woman's trajectory, it optimally merges the information contained in the observations available for that woman and that contained in the sample of all women. More specifically, the EBLUP predicts the departure of her trajectory from the population-average trajectory by shrinking the observed residual  $(w_i - Z_i \alpha)$  by a factor  $GZ_i'(Z_i GZ_i' + \sigma_e^2 I_i)^{-1}$ . When the shrinkage factor is large, the predicted trajectory is close the non-preeclamptic population-average trajectory. When shrinkage factor is small, the predicted trajectory is close to the woman's observed values. The level of shrinkage depends on two quantities: (1) the number of observations (visits) available, and (2) the relative magnitude of the variability between and within women. When the number of available observations is large and the trajectories vary substantially from woman to woman, little shrinkage takes place for that woman. Conversely, when the number of visits and the woman to woman variability are small, the shrinkage is considerable. Because the shrinkage depends on the number of observations available on each woman, it varies across women.

## Third step: predict the probability of pre-eclampsia

For each binary outcome, (pre-eclampsia, preeclampsia with delivery before 37 weeks' gestation, preeclampsia with delivery from 37 weeks' gestation, diagnosis of preeclampsia before, and from 37 weeks' gestation), we estimated a generalized linear model with logit link and normal family distribution:

logit 
$$P(Y_i = 1) = \beta_0 + \beta_1 x_{i,1} + \dots + \beta_p x_{i,p} + \beta_{p+1} u_{i,1} + \dots + \beta_{i,p+q} u_{i,q}$$

where  $Y_i$  indicates the binary outcome of the i-th woman,  $x_{i,j}$  the j-th of her p covariates, and  $u_{i,j}$  the j-th of her q u-scores. The baseline predictors were: maternal age at baseline, region of birth, family situation, height, smoking 3 months before pregnancy and at first antenatal visit, previous miscarriage, infertility duration, infertility treatment, family history of preeclampsia and hypertension, chronic diseases (cardiovascular disease, endocrine disease, pre-excisting diabetes, thrombosis history, systemic lupus erythematosus (SLE), chronic hypertension, Mb Crohn/Ulcerative colitis, kidney disease and blood group . The time-varying predictors capillary glucose and proteinuria were treated as binary and categorical, respectively. The u-scores were calculated for systolic blood pressure, diastolic blood pressure, maternal weight, symphysis fundal height and haemoglobin level. The baseline predictors, capillary glucose, proteinuria and the u-scores entered the predictive models without any further selection.

## On the estimation of the standard errors

The three-step approach described above implied that the standard errors for the coefficients  $\beta$  of the logistic regression calculated in Step 3 were possibly underestimated, as they did not take into account the uncertainty inherent in the estimates of the quantities obtained in Steps 1 and 2. Bootstrapping the full three-step process or maximizing the joint likelihood would provide correct standard errors. We performed neither of these alternative approaches, however, because standard errors, p-values, and confidence intervals, were inconsequential in any of the above steps. In addition, bootstrapping or maximizing a joint likelihood with our large sample was unfeasible with the computing resources available to us.

#### Assessment of the performance of the predictive models

The goodness of fit of the model as assessed with the Hosmer-Lemeshow test and its sensitivity and specificity were summarized by the area under the curve (AUC), and by sensitivity for 10% false positive rate.

We assessed the performance of the predictive models under five different scenarios: 1) included all available visits up to 24 fully gestational weeks (168 days), 2) all visits up to 28 gestational weeks (196 days), 3) all visits up to 32 gestational weeks (224 days), 4) all visits up to 34 gestational weeks (238 days) and 5) all visits up to 36 gestational weeks (252 days). The scenarios allowed evaluating the performance of the predictive models when the measures of the time-varying predictors at future visits are still unknown. At the 24<sup>th</sup> gestational week prediction, the u-scores for symphysis fundal height were unavailable, as this predictor is generally measured at later times during gestation.

The number of visits available on each women varied across the five scenarios, which meant that the number of rows of the vector  $w_i$  and of the matrices  $Z_i$  and  $I_i$  for the calculation of the uscores in the second step also varied across scenarios. The parameters  $\alpha$ ,  $\beta$ , and  $\gamma$ , however, were constant across the scenarios, as these were estimated in the first and third step.

**Table S1.** Number of observations of time-varying predictive variables in antenatal care in nulliparous women

#### Number of observations in antenatal care

Longitudinal predictive variables in antenatal care		Overall		Without preeclampsia		With preeclampsia	
	Missing (N)	Median	10 <sup>th</sup> , 90 <sup>th</sup> percentile	Median	10 <sup>th</sup> , 90 <sup>th</sup> percentile	Median	10 <sup>th</sup> , 90 <sup>th</sup> percentile
Visits to antenatal care		11	8, 22	11	8, 22	12	7, 24
Systolic blood pressure, mmHg		10	7, 20	10	7, 20	11	7, 22
Diastolic blood pressure, mmHg	2	10	7, 20	10	7, 20	11	7, 22
Weight, kg	1 092	6	2, 12	6	2, 12	6	2, 13
Hemoglobin (Hb), g/L	9	6	3, 12	6	3, 12	5	3, 12
Symphysis-fundal height, cm	252	8	5, 16	8	5, 16	7	4, 14
Capillary glucose, mmol/L	145	5	2, 10	5	2, 10	5	2, 10
Proteinuria, dipstick 0-4	1 316	4	1, 10	4	1, 10	6	2, 16

**Table S2.** Mean U-scores for level, trend and curvature trajectories of the time-varying predictive variables in antenatal care, by preeclampsia, in nulliparous women

	Mean U-scores of time-varying Predictors*			
Time-varying predictors	Without preeclampsia n= 56 323	With preeclampsia n=2 576	P-Value	
Systolic blood pressure				
Level	.001017	4682232	< 0.001	
Trend	0000319	.0151942	< 0.001	
Curvature	0155968	9.660262	< 0.001	
Diastolic blood pressure				
Level	0002188	4527302	< 0.001	
Trend	-2.85e-06	.0147889	< 0.001	
Curvature	0049667	8.066177	< 0.001	
Haemoglobin (Hb)				
Level	0024374	.1954536	< 0.001	
Trend	.0000484	0045065	< 0.001	
Curvature	.014297	2157052	0.35	
Weight (kg)				
Level	.0015437	1324119	< 0.001	
Trend	0000333	.0042093	< 0.001	
Curvature	0410137	5.102106	< 0.001	
Symphysis-fundal height				
Level	.0007745	0232342	0.052	
Trend	0000137	.0005151	0.005	
Curvature	0118639	.3410827	0.071	

<sup>\*</sup> For each time-varying predictor, a set of three u-scores captured the departure of each woman's trajectory from the non-preeclamptic population average trajectory with respect to three features: level, trend, and curvature. A positive or negative u-score indicates that the feature is larger or smaller than that of the non-preeclamptic population.

**Table S3**. Performance of the prediction models for diagnosis of preeclampsia < 37 weeks' and  $\ge 37$  weeks' gestation (irrespective of gestational age at delivery) at different gestational ages

	Diagnosis of preeclampsia < 37 weeks				Diagnosis of preeclampsia ≥ 37 weeks			
Gestational age of prediction* (weeks)	AUC <sup>†</sup>	(95% CI)	Sensitivity for 10% FPR <sup>‡</sup>	(95% CI)	AUC <sup>†</sup>	(95% CI)	Sensitivit y for 10% FPR <sup>‡</sup>	(95% CI)
24	0.74	(0.70 - 0.79)	37.5	(29.8-45.7)	0.63	(0.60 - 0.66)	21.8	(17.3-26.9)
28	0.78	(0.76 - 0.80)	41.2	(37.1-45.3)	0.64	(0.63-0.66)	21.7	(19.6-23.9)
32	0.83	(0.81-0.85)	56.5	(52.1-60.9)	0.67	(0.66-0.69)	25.4	(23.2-27.7)
34	0.86	(0.83-0.88)	64.1	(59.1-69.0)	0.71	(0.70 - 0.73)	31.3	(28.9-33.7)
36	0.88	(0.85 - 0.91)	69.6	(61.2-77.1)	0.77	(0.75-0.78)	40.4	(37.9-43.0)

<sup>\*</sup>The model is composed of the predictive variables collected at first antenatal visit, the time-varying predictors plasma glucose and proteinuria, and the u-scores of level, trend and curvature for each of the time-varying predictors systolic and diastolic blood pressure, haemoglobin, maternal weigh and symphysis fundal height up until the gestational week of prediction (24, 28, 32, 34 and 36).

<sup>&</sup>lt;sup>†</sup>AUC: Area under receiver operating characteristic curve

<sup>&</sup>lt;sup>‡</sup>FPR: False positive rate

**Table S4.** Sensitivity analysis excluding women with aspirin treatment during pregnancy. Performance of the predictive models for diagnosis of preeclampsia at different gestational ages during pregnancy (N=58 276)

	Preeclampsia					
Gestational age of prediction* (weeks)	AUC <sup>†</sup>	(95% CI)	Sensitivity for 10% FPR <sup>‡</sup>	(95% CI)		
24	0.68	(0.66- 0.71)	28.7	(24.5- 33.0)		
28	0.70	(0.69 - 0.71)	29.9	(27.9-31.9)		
32	0.73	(0.72 - 0.75)	35.2	(33.0-37.3)		
34	0.77	(0.75 - 0.78)	41.0	(38.8-43.3)		
36	0.80	(0.78 - 0.81)	46.4	(44.0-48.9)		

<sup>\*</sup>The model is composed of the predictive variables collected at first antenatal visit, the time-varying predictors plasma glucose and proteinuria, and the u-scores of level, trend and curvature for each of the time-varying predictors systolic and diastolic blood pressure, haemoglobin, maternal weigh and symphysis fundal height up until the gestational week of prediction (24, 28, 32, 34 and 36).

<sup>†</sup> ÂUC: Area under receiver operating characteristic curve

<sup>&</sup>lt;sup>‡</sup> FPR: False positive rate

**Table S5:** Coefficients of the parameters of the predictive model

Maternal age at first antenatal visit         0.0163         0.0405         -0.0015           Height         -0.0277         -0.0315         -0.015           Previous miscarriage         -0.0025         -0.0011         -0.002           Infertility duration         0.0033         0.0585         -0.033           Infertility treatment         0.1643         0.0442         0.078           Ovary stimulation         0.1153         -0.1235         0.304           Family situation         ref	Predictive variables	Diagnosis of Preeclampsia overall	Diagnosis of preeclampsia < gw 37	Diagnosis of preeclampsia ≥ gw 37
Height   -0.0277   -0.0315   -0.015       Previous miscarriage   -0.0025   -0.0011   -0.004     Infertility duration   0.0033   0.0585   -0.033     Infertility treatment       Ovary stimulation   0.1643   0.0442   0.078     IVF   0.1153   -0.1235   0.304     Family situation   ref   ref   ref   ref     Single   0.1141   0.4487   0.007     Other   0.0110   0.0628   -0.033     Region of birth       Sweden   ref   ref   ref   ref   ref     Nordic countries (except of Sweden)   -0.1436   -0.3545   -0.055     Europe (except of Nordic countries)   -0.3207   -0.3189   -0.266     Africa   0.4370   0.4796   0.177     North America   -0.1677   -0.1154   -0.267     South America   -0.2766   0.2741   -0.335     Oceania   -1.8542   -   -0.308     Smoking 3 months before pregnancy   -0.0439   -0.278     Smoking 4 first antenatal visi   -1.05   -0.372   -0.4369   -0.275     Smoking at first antenatal visi   -1.05   -0.1874   0.3583   -0.305     Family history of preeclampsia   0.2449   0.2635   -0.065     Family history of hypertension   -0.0010   0.0077   -0.015     Cardiovascular disease   0.0503   -0.4509   0.105     Endocrine disease   0.0503   -0.4509   0.105     Cardiovascular disease   0.0503   -0.2504   0.2504     Cardio	Constant	-0.8929	-2.8400	-2.2478
Height         -0.0277         -0.0315         -0.015           Previous miscarriage         -0.0025         -0.0011         -0.002           Infertility duration         0.0033         0.0585         -0.033           Infertility treatment         0.1643         0.0442         0.078           IVF         0.1153         -0.1235         0.304           Family situation         ref         region of the         0.0010         0.0628         -0.031         0.002         0.003         0	Maternal age at first antenatal visit	0.0163	0.0405	-0.0009
Previous miscarriage	_	-0.0277	-0.0315	-0.0153
Infertility treatment           Ovary stimulation         0.1643         0.0442         0.078           IVF         0.1153         -0.1235         0.304           Family situation           Living together with partner         ref	_	-0.0025	-0.0011	-0.0045
Ovary stimulation         0.1643         0.0442         0.078           IVF         0.1153         -0.1235         0.304           Family situation	Infertility duration	0.0033	0.0585	-0.0336
Family situation   Living together with partner   ref   r	Infertility treatment			
Family situation         ref	Ovary stimulation	0.1643	0.0442	0.0785
Living together with partner         ref         ref         ref           Single         0.1141         0.4487         0.007           Other         0.0110         0.0628         -0.031           Region of birth         Tef         ref	-	0.1153	-0.1235	0.3040
Living together with partner         ref         ref         ref           Single         0.1141         0.4487         0.007           Other         0.0110         0.0628         -0.031           Region of birth         Tef         ref	Family situation			
Single       0.1141       0.4487       0.007         Other       0.0110       0.0628       -0.031         Region of birth       Sweden       ref	-	ref	ref	ref
Other         0.0110         0.0628         -0.031           Region of birth         Sweden         ref         red         red.055         col.052         col.053         col.264         col.265         col.266         col.274         col.263         col.263         col.264         col.275         col.262         col.262         col.2632         <		0.1141	0.4487	0.0079
Sweden         ref         red         redoctor         red	_	0.0110	0.0628	-0.0316
Sweden         ref         red         redoctor         red	Region of birth			
Europe (except of Nordic countries)  Africa  Africa  0.4370  0.4796  0.177  North America  -0.1677  -0.1154  -0.266  South America  -0.2766  0.2741  -0.332  Asia  -0.2035  0.0361  -0.278  Oceania  -1.8542  -0.308  Smoking 3 months before pregnancy  <10  -0.1539  -0.3721  -0.4369  -0.275  Smoking at first antenatal visit  <10  -0.1874  0.3583  -0.303  ≥10  -0.1874  0.3583  -0.303  ≥10  -0.1874  0.3583  -0.303  -0.225  Family history of preeclampsia  0.2449  0.2635  -0.065  Family history of hypertension  -0.0010  0.0077  -0.013  Cardiovascular disease  0.0026  -0.3339  0.156	_	ref	ref	ref
Europe (except of Nordic countries)  Africa  O.4370  O.4796  O.177  North America  O.2666  South America  O.2766  O.2741  O.2786  Oceania  O.2035  Oceania  O.2035  Oceania  O.2035  Smoking 3 months before pregnancy  <10  ○0.1539  ○0.3721  ○0.3721  ○0.3729  ○0.3721  ○0.383  ○0.361  ○0.2785  Smoking at first antenatal visit  <10  ○0.1539  ○0.3721  ○0.4369  ○0.2755  Smoking at first antenatal visit  <10  ○0.1874  ○0.3583  ○0.3033  ○10  ○10  Family history of preeclampsia  Family history of hypertension  O.2449  O.2635  Family history of hypertension  O.0010  O.0077  Cardiovascular disease  O.0026  O.03339  O.1566	Nordic countries (except of Sweden)	-0.1436	-0.3545	-0.0551
Africa 0.4370 0.4796 0.177 North America -0.1677 -0.1154 -0.267 South America -0.2766 0.2741 -0.332 Asia -0.2035 0.0361 -0.278 Oceania -1.85420.308 Smoking 3 months before pregnancy <10 -0.1539 -0.2379 -0.062 ≥10 -0.3721 -0.4369 -0.275 Smoking at first antenatal visit <10 -0.1874 0.3583 -0.303 ≥10 -0.3584 0.5514 0.225 Family history of preeclampsia 0.2449 0.2635 -0.065 Family history of hypertension -0.0010 0.0077 -0.013 Cardiovascular disease 0.0503 -0.4509 0.108 Endocrine disease 0.0026 -0.3339 0.156		-0.3207	-0.3189	-0.2687
North America       -0.1677       -0.1154       -0.265         South America       -0.2766       0.2741       -0.332         Asia       -0.2035       0.0361       -0.278         Oceania       -1.8542       -       -0.308         Smoking 3 months before pregnancy       -0.1539       -0.2379       -0.064         ≥10       -0.3721       -0.4369       -0.275         Smoking at first antenatal visit       -0.1874       0.3583       -0.303         ≥10       -0.1874       0.3583       -0.303         ≥10       0.3584       0.5514       0.225         Family history of preeclampsia       0.2449       0.2635       -0.065         Family history of hypertension       -0.0010       0.0077       -0.013         Cardiovascular disease       0.0503       -0.4509       0.108         Endocrine disease       0.0026       -0.3339       0.150		0.4370	0.4796	0.1777
Asia       -0.2035       0.0361       -0.278         Oceania       -1.8542       -       -0.308         Smoking 3 months before pregnancy       -0.1539       -0.2379       -0.064         ≥10       -0.3721       -0.4369       -0.275         Smoking at first antenatal visit       -0.1874       0.3583       -0.303         ≥10       -0.1874       0.3583       -0.303         ≥10       0.3584       0.5514       0.225         Family history of preeclampsia       0.2449       0.2635       -0.065         Family history of hypertension       -0.0010       0.0077       -0.013         Cardiovascular disease       0.0503       -0.4509       0.108         Endocrine disease       0.0026       -0.3339       0.150		-0.1677	-0.1154	-0.2676
Asia       -0.2035       0.0361       -0.278         Oceania       -1.8542       -       -0.308         Smoking 3 months before pregnancy       -0.1539       -0.2379       -0.064         ≥10       -0.3721       -0.4369       -0.275         Smoking at first antenatal visit       -0.1874       0.3583       -0.303         ≥10       -0.1874       0.3583       -0.303         ≥10       0.3584       0.5514       0.225         Family history of preeclampsia       0.2449       0.2635       -0.065         Family history of hypertension       -0.0010       0.0077       -0.013         Cardiovascular disease       0.0503       -0.4509       0.108         Endocrine disease       0.0026       -0.3339       0.150	South America	-0.2766	0.2741	-0.3323
Smoking 3 months before pregnancy         <10		-0.2035	0.0361	-0.2782
<10	Oceania	-1.8542	-	-0.3087
<10	Smoking 3 months before pregnancy			
$\geq 10$ -0.3721 -0.4369 -0.275  Smoking at first antenatal visit <10 -0.1874 0.3583 -0.303 ≥10 0.3584 0.5514 0.225  Family history of preeclampsia 0.2449 0.2635 -0.065  Family history of hypertension -0.0010 0.0077 -0.013  Cardiovascular disease 0.0503 -0.4509 0.108  Endocrine disease 0.0026 -0.3339 0.156		-0.1539	-0.2379	-0.0643
Smoking at first antenatal visit         <10	≥10	-0.3721	-0.4369	-0.2750
<10				
Family history of preeclampsia         0.2449         0.2635         -0.065           Family history of hypertension         -0.0010         0.0077         -0.013           Cardiovascular disease         0.0503         -0.4509         0.108           Endocrine disease         0.0026         -0.3339         0.150	_	-0.1874	0.3583	-0.3033
Family history of preeclampsia         0.2449         0.2635         -0.065           Family history of hypertension         -0.0010         0.0077         -0.013           Cardiovascular disease         0.0503         -0.4509         0.108           Endocrine disease         0.0026         -0.3339         0.150	≥10	0.3584	0.5514	0.2250
Family history of hypertension         -0.0010         0.0077         -0.013           Cardiovascular disease         0.0503         -0.4509         0.108           Endocrine disease         0.0026         -0.3339         0.150		0.2449	0.2635	-0.0656
Cardiovascular disease         0.0503         -0.4509         0.108           Endocrine disease         0.0026         -0.3339         0.150		-0.0010	0.0077	-0.0132
	· · · · · · ·	0.0503	-0.4509	0.1086
Due existing dishetes 0.0229 1.0462 0.723		0.0026	-0.3339	0.1501
-0.0228 1.0402 -0.721	Pre-existing diabetes	-0.0228	1.0462	-0.7219
Thrombosis				
SLE n (%)		-0.2917	-0 6951	-0.0636
<b>*</b> •	V 2			-0.4422
<b>Chronic kidney disease</b> 0.0245 0.3081 0.045	Chronic kidney disease			0.0458
Blood group		2	2	2
				ref 0.0104
				-0.0181

В	0.0684	0.1646	-0.0038
Systolic blood pressure			
Level	2.3122	1.7770	1.5400
Trend	108.8857	59.9576	84.1703
Curvature	0.0392	0.0334	0.0290
Diastolic blood pressure			
Level	4.6273	7.2351	1.8809
Trend	190.4049	270.3426	92.0414
Curvature	0.0967	0.1421	0.0459
Hemoglobin (Hb)			
Level	0.0798	0.5894	-0.2069
Trend	1.1189	16.0010	-7.4970
Curvature	-0.0008	0.0129	-0.0067
Weight (kg)			
Level	1.3098	1.4453	0.8698
Trend	94.1729	98.9102	61.1168
Curvature	0.0057	0.0037	0.0073
Symphysis-fundal height			
Level	-4.6849	-11.5770	0.9998
Trend	-156.4996	-398.3259	43.3697
Curvature	-0.1442	-0.3375	0.0168
Capillary glucose	-0.0526	0.0035	-0.0350
Protein in urine	1.5585	1.3116	1.2644

Table S6. Parameters of the mixed effect model

Predictive variables	Systolic blood	Diastolic blood	Weight	Hb	Symphysis-
	pressure	pressure			fundal
Level	114.6837	72.7151	61.6429	143.4706	-12.0752
Trend (time_1)	-0.4742	-0.7969	0.2947	-2.0566	1.8301
Curvature (time_2)	0.0129	0.0199	0.0044	0.0412	-0.0156
log(gamma11)	0.1272	-0.1454	-0.8851	0.3829	-0.2697
log(gamma22)	-3.7747	-4.0120	-4.7969	-3.4735	-4.4372
log(gamma33)	2.7192	2.4180	2.4933	2.7959	2.4914
arctan(gamma12)	-2.1036	-2.0763	-1.5960	-2.1504	-2.8509
arctan(gamma13)	-1.1099	-1.2099	-0.4048	-1.2888	-2.7268
arctan(gamma23)	0.8912	0.9801	0.3597	1.0066	2.1539
log(sigma_e)	1.8553	1.5810	-0.0586	1.7188	-0.6552